Stock listing
OTC:SCPS Scopus BioPharma, Inc. Stock
Follow Scopus BioPharma, Inc. into a list and get an email when it puts out news.
Share price · OTC:SCPS
$0.0004 USD 0.0000 (0.0%)
Close on Oct 26, 2026
- Day range
- $0.0004 – $0.0004 USDOct 26, 2026
- Volume
- 1,800 sharesOct 26, 2026
- Market cap
- $16,834 USDAt the close on Oct 26, 2026 · price × 42.08M shares outstanding
- 52-week range
- $0.0003 – $0.0100 USDLowest and highest trades, Oct 27, 2025 – Oct 26, 2026
- Traded on an average day
- $2 USDMedian day 0 shares · 33 days with no trades · last 3 months, Jul 27, 2026 – Oct 26, 2026

Daily closes
Last 3 months, Jul 27, 2026 – Oct 26, 2026 · OTC:SCPS · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.0004 | 0.0000 | 0.0% | $0.0004 | $0.0004 | $0.0004 | 1,800 | |
| $0.0004 | 0.0000 | 0.0% | $0.0004 | $0.0004 | $0.0004 | 0 | |
| $0.0004 | 0.0000 | 0.0% | $0.0004 | $0.0004 | $0.0004 | 150,025 | |
| $0.0004 | 0.0000 | 0.0% | $0.0004 | $0.0004 | $0.0004 | 0 | |
| $0.0004 | 0.0000 | 0.0% | $0.0004 | $0.0004 | $0.0004 | 100 | |
| $0.0004 | 0.0000 | 0.0% | $0.0004 | $0.0004 | $0.0004 | 0 | |
| $0.0004 | 0.0000 | 0.0% | $0.0004 | $0.0004 | $0.0004 | 0 | |
| $0.0004 | 0.0000 | 0.0% | $0.0004 | $0.0004 | $0.0004 | 385 | |
| $0.0004 | 0.0000 | 0.0% | $0.0004 | $0.0004 | $0.0004 | 150 | |
| $0.0004 | -0.0002 | -33.3% | $0.0004 | $0.0004 | $0.0004 | 1,000 | |
| $0.0006 | +0.0002 | +50.0% | $0.0006 | $0.0006 | $0.0006 | 269 | |
| $0.0004 | 0.0000 | 0.0% | $0.0004 | $0.0004 | $0.0004 | 2,000 | |
| $0.0004 | 0.0000 | 0.0% | $0.0004 | $0.0004 | $0.0004 | 501 | |
| $0.0004 | 0.0000 | 0.0% | $0.0004 | $0.0004 | $0.0004 | 448 | |
| $0.0004 | 0.0000 | 0.0% | $0.0004 | $0.0004 | $0.0004 | 0 | |
| $0.0004 | 0.0000 | 0.0% | $0.0004 | $0.0004 | $0.0004 | 0 | |
| $0.0004 | 0.0000 | 0.0% | $0.0004 | $0.0004 | $0.0004 | 0 | |
| $0.0004 | 0.0000 | 0.0% | $0.0004 | $0.0004 | $0.0004 | 0 | |
| $0.0004 | -0.0002 | -33.3% | $0.0004 | $0.0004 | $0.0004 | 32,052 | |
| $0.0006 | 0.0000 | 0.0% | $0.0006 | $0.0006 | $0.0006 | 0 | |
| $0.0006 | 0.0000 | 0.0% | $0.0006 | $0.0006 | $0.0006 | 0 | |
| $0.0006 | 0.0000 | 0.0% | $0.0006 | $0.0006 | $0.0006 | 0 | |
| $0.0006 | 0.0000 | 0.0% | $0.0006 | $0.0006 | $0.0006 | 0 | |
| $0.0006 | 0.0000 | 0.0% | $0.0006 | $0.0006 | $0.0006 | 0 | |
| $0.0006 | 0.0000 | 0.0% | $0.0006 | $0.0006 | $0.0006 | 0 | |
| $0.0006 | 0.0000 | 0.0% | $0.0006 | $0.0006 | $0.0006 | 5,002 | |
| $0.0006 | +0.0002 | +50.0% | $0.0006 | $0.0006 | $0.0006 | 2,824 | |
| $0.0004 | 0.0000 | 0.0% | $0.0004 | $0.0004 | $0.0004 | 500 | |
| $0.0004 | 0.0000 | 0.0% | $0.0004 | $0.0004 | $0.0004 | 0 | |
| $0.0004 | 0.0000 | 0.0% | $0.0004 | $0.0004 | $0.0004 | 0 | |
| $0.0004 | 0.0000 | 0.0% | $0.0004 | $0.0004 | $0.0004 | 47,076 | |
| $0.0004 | 0.0000 | 0.0% | $0.0004 | $0.0004 | $0.0004 | 0 | |
| $0.0004 | 0.0000 | 0.0% | $0.0004 | $0.0004 | $0.0004 | 0 | |
| $0.0004 | 0.0000 | 0.0% | $0.0004 | $0.0004 | $0.0004 | 0 | |
| $0.0004 | 0.0000 | 0.0% | $0.0004 | $0.0004 | $0.0004 | 0 | |
| $0.0004 | 0.0000 | 0.0% | $0.0004 | $0.0004 | $0.0004 | 0 | |
| $0.0004 | 0.0000 | 0.0% | $0.0004 | $0.0004 | $0.0004 | 0 | |
| $0.0004 | 0.0000 | 0.0% | $0.0004 | $0.0004 | $0.0004 | 1,199 | |
| $0.0004 | 0.0000 | 0.0% | $0.0004 | $0.0004 | $0.0004 | 0 | |
| $0.0004 | 0.0000 | 0.0% | $0.0004 | $0.0004 | $0.0004 | 200 | |
| $0.0004 | 0.0000 | 0.0% | $0.0004 | $0.0004 | $0.0004 | 0 | |
| $0.0004 | 0.0000 | 0.0% | $0.0004 | $0.0004 | $0.0004 | 0 | |
| $0.0004 | 0.0000 | 0.0% | $0.0004 | $0.0004 | $0.0004 | 489 | |
| $0.0004 | 0.0000 | 0.0% | $0.0004 | $0.0004 | $0.0004 | 1,100 | |
| $0.0004 | 0.0000 | 0.0% | $0.0004 | $0.0004 | $0.0004 | 134 | |
| $0.0004 | 0.0000 | 0.0% | $0.0004 | $0.0004 | $0.0004 | 5,901 | |
| $0.0004 | 0.0000 | 0.0% | $0.0004 | $0.0004 | $0.0004 | 0 | |
| $0.0004 | 0.0000 | 0.0% | $0.0004 | $0.0004 | $0.0004 | 1,468 | |
| $0.0004 | 0.0000 | 0.0% | $0.0004 | $0.0004 | $0.0004 | 123 | |
| $0.0004 | 0.0000 | 0.0% | $0.0004 | $0.0004 | $0.0004 | 125 | |
| $0.0004 | 0.0000 | 0.0% | $0.0004 | $0.0004 | $0.0004 | 0 | |
| $0.0004 | 0.0000 | 0.0% | $0.0004 | $0.0004 | $0.0004 | 0 | |
| $0.0004 | 0.0000 | 0.0% | $0.0004 | $0.0004 | $0.0004 | 0 | |
| $0.0004 | 0.0000 | 0.0% | $0.0004 | $0.0004 | $0.0004 | 0 | |
| $0.0004 | 0.0000 | 0.0% | $0.0004 | $0.0004 | $0.0004 | 0 | |
| $0.0004 | 0.0000 | 0.0% | $0.0004 | $0.0004 | $0.0004 | 3,000 | |
| $0.0004 | -0.0001 | -20.0% | $0.0004 | $0.0004 | $0.0004 | 580 | |
| $0.0005 | 0.0000 | 0.0% | $0.0005 | $0.0005 | $0.0005 | 0 | |
| $0.0005 | 0.0000 | 0.0% | $0.0005 | $0.0005 | $0.0005 | 0 |
- Ticker
- OTC:SCPS
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- OTC
- Currency
- USD
Latest news
Scopus BioPharma, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 3 in all · newest Nov 7, 2023 · oldest 2022
- Decks
- 10 decks · latest Mar 23, 2022
Valuation
price Oct 26, 2026
- Enterprise value
- No statements on 6ix yet
- P/E
- No statements on 6ix yet
- EV/sales
- No statements on 6ix yet
- EV/EBITDA
- No statements on 6ix yet
- Price/book
- No statements on 6ix yet
- Gross margin
- No statements on 6ix yet
- Operating margin
- No statements on 6ix yet
- Net margin
- No statements on 6ix yet
- Debt to equity
- No statements on 6ix yet
- Beta vs S&P 500
- 1.32
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Scopus BioPharma, Inc. · OTC:SCPS | US$16,834 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 1.32 |
| Vaxil Bio Ltd. · TSXV:VXL | US$319,477 | −US$4,071 | 1.2× | n/a | n/a | 0.4× | n/a | 0.0× | -0.16 |
| Chimeric Therapeutics Limited · ASX:CHM | US$292,816 | −US$220,193 | n/a | −0.1× | n/a | 0.2× | −262.8% | 2.5× | n/a |
| CERo Therapeutics Holdings, Inc. · OTC:CERO | US$265,035 | −US$190,890 | n/a | n/a | n/a | n/a | n/a | n/a | 1.47 |
| CDT Equity Inc. · NASDAQ:CDT | US$234,109 | −US$1.49M | n/a | n/a | n/a | 0.0× | n/a | 0.0× | 1.14 |
| GlucoTrack, Inc. · NASDAQ:GCTK | US$217,049 | −US$887,951 | n/a | n/a | n/a | n/a | n/a | n/a | 1.73 |
| Regen BioPharma, Inc. · OTC:RGBP | US$167,528 | US$167,289 | n/a | 0.7× | n/a | n/a | −501.4% | n/a | 1.20 |
| CNBX Pharmaceuticals Inc. · OTC:CNBX | US$160,577 | US$151,090 | n/a | n/a | n/a | n/a | n/a | n/a | 1.78 |
| Fifty 1 Labs Inc. · OTC:FITY | US$118,532 | US$282,021 | n/a | 6,000× | n/a | n/a | n/a | n/a | -1.17 |
| GB Sciences, Inc. · OTC:GBLX | US$81,414 | US$2.07M | n/a | n/a | n/a | n/a | n/a | n/a | -0.46 |
| Lyra Therapeutics, Inc. · OTC:LYRA | US$53,246 | US$14.42M | n/a | 36.2× | n/a | n/a | n/a | n/a | 0.67 |
| Median of the others | US$192,289 | US$73,510 | 1.2× | 18.5× | 0.2× | −382.1% | 0.0× | 1.14 |
Events
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Dec 31, 2025 | Feb 25, 2026 | 0.0% |
| Quarter to Sep 30, 2025 | Dec 3, 2025 | +25.0% |
| Quarter to Jun 30, 2025 | Sep 3, 2025 | 0.0% |
| Quarter to Mar 31, 2025 | May 28, 2025 | 0.0% |
| Quarter to Dec 31, 2024 | Feb 26, 2025 | 0.0% |
| Quarter to Sep 30, 2024 | Nov 27, 2024 | 0.0% |
| Quarter to Jun 30, 2024 | Aug 28, 2024 | 0.0% |
| Quarter to Mar 31, 2024 | May 29, 2024 | −90.5% |
| Quarter to Dec 31, 2023 | Feb 28, 2024 | +5.0% |
| Quarter to Sep 30, 2023 | Nov 29, 2023 | −11.9% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q2 2023 | Aug 11, 2023 · After close | −37.1% |
| Q1 2023 | May 12, 2023 · After close | 0.0% |
| Q4 2022 | Mar 1, 2023 | −6.3% |
| Q3 2022 | Nov 21, 2022 | −16.8% |
| Q2 2022 | Aug 31, 2022 | −5.7% |
| Q1 2022 | Apr 15, 2022 · After close | −5.9% |
| Q4 2021 | Mar 2, 2022 | −3.9% |
| Q3 2021 | Nov 12, 2021 · After close | +0.9% |
| Q2 2021 | Aug 13, 2021 · After close | −6.2% |
| Q1 2021 | May 17, 2021 · After close | −2.6% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| STING & TLR-Targeting Therapies Summit 2022 | Conference | 18 slides | Mar 23, 2022 |
| Corporate Update (September 2021) | Corporate update | 21 slides | Sep 13, 2021 |
| Investor Presentation (September 2021) | Investor deck | 21 slides | September 2021 |
| Investor Presentation (January 2021) | Investor deck | 21 slides | Jan 20, 2021 |
| Investor Presentation (January 2021) | Investor deck | 19 slides | January 2021 |
| Investor Presentation (December 2020) | Investor deck | 19 slides | December 2020 |
| IPO Roadshow (September 2020) | IPO roadshow | 33 slides | September 2020 |
| Investor Presentation (September 2020) | Investor deck | 29 slides | September 2020 |
| IPO Roadshow (October 2019) | IPO roadshow | 16 slides | Oct 2, 2019 |
| IPO Roadshow (September 2019) | IPO roadshow | 15 slides | Sep 27, 2019 |
Financials
Annual, in USD
Income statement
| Line | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and development | 2.68M | 15.0M | 7.42M | 463.1K | 277.5K | |
| Selling, general and administrative | 9.03M | 12.6M | 2.73M | 2.23M | 408.4K | |
| Operating income | -11.7M | -27.6M | -10.2M | -2.69M | -686.0K | |
| Depreciation and amortization | 1.73K | 1.50K | 1.44K | 664 | 664 | 664 |
| EBITDA | -11.7M | -27.6M | -10.2M | -2.69M | -685.3K | |
| Interest expense | 0 | 774.7K | 706.4K | 0 | 0 | 0 |
| Income before tax | -11.7M | -27.0M | -10.9M | -2.69M | -686.0K | |
| Income tax | -105.0K | -1.46M | 706.4K | 1 | ||
| Net income | -11.6M | -25.5M | -11.6M | -2.69M | -686.0K | |
| Earnings per share, basic | -0.55 | -1.48 | -0.87 | -0.18 | -0.05 |
Balance sheet
| Line | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|
| Cash and equivalents | 124.6K | 7.94M | 1.83M | 36.7K | 1.66K | 158.2K |
| Receivables | 562 | 27.9K | 54.7K | |||
| Inventory | 730.7K | |||||
| Current assets | 390.0K | 8.18M | 1.97M | 768.0K | 132.6K | 212.9K |
| Property, plant and equipment | 2.27K | 2.84K | 2.33K | 3.66K | ||
| Total assets | 392.3K | 8.19M | 1.97M | 771.7K | 132.6K | 212.9K |
| Accounts payable | 175.6K | 116.1K | 1.52M | 163.1K | ||
| Current liabilities | 7.45M | 4.17M | 3.81M | 854.5K | 138.0K | 111.3K |
| Total debt | 2.28M | |||||
| Total liabilities | 7.45M | 4.17M | 3.81M | 854.5K | 138.0K | 111.3K |
| Shareholders' equity | -7.06M | 4.02M | -1.83M | -82.9K | -5.33K | 101.6K |
| Shares outstanding | 21.1M | 17.3M | 13.4M | 15.0M | 15.0M | 15.0M |
Cash flow
| Line | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|
| Cash from operations | -8.13M | -11.4M | -2.53M | -2.12M | -747.3K | -228.4K |
| Capital spending | -1.55K | -2.00K | -2.00K | -4.25K | -4.25K | -4.25K |
| Free cash flow | -8.13M | -11.4M | -2.53M | -2.12M | -747.3K | -232.6K |
| Cash from investing | -1.55K | -2.00K | -2.00K | -4.25K | -4.25K | -4.25K |
| Cash from financing | 241.9K | 17.6M | 4.35M | 2.18M | 597.6K | 465.7K |
| Change in cash | -7.82M | 6.11M | 1.80M | 35.1K | -156.6K | 237.3K |
Cap table
Built by 6ix from Scopus BioPharma, Inc.’s releases
- Common shares
- 42,084,264
- Fully diluted
- 42,084,264
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 42,084,264 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 42,084,264 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Lesley Russell Other companies: Enanta Pharmaceuticals, Inc. (Director · Since at least Nov 18, 2016); Innocoll AG (Chief Medical Officer · Jan 1, 2017 – Jul 24, 2017 · Past); Tetralogic Pharmaceuticals Corp (Chief Operating Officer · Dec 11, 2013 – Jan 28, 2015 · Past); Endocyte Inc (Director · Jan 4, 2013 – Dec 21, 2018 · Past); AMAG Pharmaceuticals Inc (Director · Dec 16, 2009 – Jun 7, 2018 · Past); Cephalon Inc (Exec VP, Chief Medical Off · Sep 1, 2006 – Oct 14, 2011 · Past) | Director · Dec 16, 2020 – Dec 16, 2020 · Past |
| David Weild IV Other companies: High Roller Technologies, Inc. (Director · Since at least Oct 23, 2024); PAVmed Inc. (Director · Feb 14, 2018 – Apr 1, 2021 · Past); Streamex Corp. (Director · Nov 24, 2017 – Aug 15, 2023 · Past) | Director · Dec 16, 2020 – Dec 16, 2020 · Past |
| David S Battleman Other companies: Lipella Pharmaceuticals, Inc. (Director · Dec 19, 2022 – Jun 16, 2023 · Past); PAVmed Inc. (Director · Aug 3, 2017 – Apr 1, 2021 · Past) | Director · Dec 16, 2020 – Dec 16, 2020 · Past |
| Paul Hopper Other companies: Fibrocell Science Inc (Director · Sep 3, 2009 – Sep 25, 2009 · Past); EyePoint, Inc. (Director · Jul 9, 2008 – Dec 18, 2013 · Past) | Director · Dec 15, 2020 – Jun 1, 2021 · Past |
| David A Buckel Other companies: SharpSpring Inc (Director · Jan 13, 2014 – Sep 1, 2021 · Past) | Director · Dec 16, 2020 – Dec 16, 2020 · Past |
| Ira Scott Greenspan Other companies: PAVmed Inc. (Director · Jan 29, 2016 – Dec 31, 2017 · Past) | Executive Committee Chairman, Director · Dec 15, 2020 – Nov 23, 2021 · Past |
| Joshua R Lamstein Other companies: PAVmed Inc. (Director · Jan 29, 2016 – Dec 21, 2017 · Past) | Chairman, Director · Dec 15, 2020 – Nov 23, 2021 · Past |
| Raphael Hofstein Other companies: BioLineRX Ltd. (Director · Since at least Mar 18, 2026) | Director · Dec 16, 2020 – Dec 16, 2020 · Past |
| Alan M Horsager | See Remarks · Jun 25, 2021 – Jun 25, 2021 · Past |
| Ashish P Sanghrajka | President, Director · Dec 15, 2020 – Dec 15, 2020 · Past |
All 11 people
| Person | Seat |
|---|---|
| Robert J Gibson | Vice Chairman, Director · Dec 15, 2020 – Feb 24, 2021 · Past |
Log in to ask 6ix AI your own questions about Scopus BioPharma, Inc.